Samsung Biologics reports third quarter 2025 financial results
— Recorded Q3'25 consolidated revenue ofKRW 1,660.2 billion — Recorded Q3'25 consolidated operating profit ofKRW 728.8 billion — Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the third quarter of fiscal year 2025. https://mma.prnewswire.com/media/2395686/Samsung_Biologics_Logo.jpg […]